Anavex Life Sciences Strengthens Board of Directors
February 13 2017 - 6:00AM
Anavex Life Sciences Corp. (“Anavex” or the
“Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical
company developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer, today announced the appointment
of Peter Donhauser, D.O. to its Board of Directors. Dr.
Donhauser has more than 20 years of expertise in clinical research
followed by practicing osteopathic medicine with an integrated
medical approach in private practice since 2000. He worked at
the University Hospital of Munich in the fields of geriatrics and
neuromusculoskeletal diseases. During this time, he was a
clinical trial investigator in multiple Phase 3 studies, including
studies sponsored by Merck Sharp & Dohme/Merck, Boehringer
Mannheim/Roche, Servier and Sanofi.
“I am excited to join the Board of Directors of
Anavex Life Sciences at this important juncture,” said Dr.
Donhauser. “Anavex has reported promising 57-week data from
its Phase 2a clinical trial in Alzheimer’s patients as well as
positive preclinical data across a broad range of CNS diseases. I
look forward to working with the team to advance the upcoming
clinical programs in Rett syndrome, Parkinson’s and Alzheimer’s
disease.”
“We are pleased to welcome Peter Donhauser, D.O.
to our Board,” said Christopher U. Missling, PhD, President and
Chief Executive Officer of Anavex. “With more than 20 years
of experience as a practicing physician and clinical trial
investigator in the areas of osteopathic and geriatric medicine, we
believe his contributions will be highly valuable as we advance our
Alzheimer’s clinical trial program into a larger,
placebo-controlled Phase 2/3 study and initiate Phase 2 trials in
Rett syndrome and Parkinson’s disease.”
Dr. Donhauser received his human medicine degree
at the University of Munich and Doctor of Osteopathic Medicine
(D.O.) from the DAAO and EROP at the Philadelphia College of
Osteopathic Medicine, Philadelphia, Pennsylvania.
About Anavex Life Sciences
Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX 2-73, recently completed successfully a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors and successfully completed Phase
1. Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer’s disease. It has also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy and others. The
Michael J. Fox Foundation for Parkinson’s Research has awarded
Anavex a research grant to develop ANAVEX 2-73 for the treatment of
Parkinson’s disease to fully fund a preclinical study, which could
justify moving ANAVEX 2-73 into a Parkinson’s disease clinical
trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease modifications against the major Alzheimer’s hallmarks in
transgenic (3xTg-AD) mice, including cognitive deficits, amyloid
and tau pathologies, and also with beneficial effects on
neuroinflammation and mitochondrial dysfunctions. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook and LinkedIn.
To receive ongoing Anavex corporate
communications, please click on the following link to join our
email alert list:
http://www.anavex.com/investors/information-request/.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com
Media:
Dennis Dobson, Jr.
Dobson Media Group
203-258-0159
dennisdobsonjr@dobsonmediagroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024